Conversely, restoration of HK2 renders miR-202 overexpressing cells resistant to imatinib (Figure 6D), indicating miR-202 sensitizes imatinib resistant CML cell lines through targetting HK2. This evidence concerns the gene HK2 and chronic myelogenous leukemia, BCR-ABL1 positive.